These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7988626)

  • 21. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.
    Kahan BD; Welsh M; Rutzky L; Lewis R; Knight R; Katz S; Napoli K; Grevel J; Van Buren CT
    Transplantation; 1992 Feb; 53(2):345-51. PubMed ID: 1738928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients.
    Choi JS; Lee SH; Chung SJ; Yoo KH; Sung KW; Koo HH
    Bone Marrow Transplant; 2006 Jul; 38(1):29-35. PubMed ID: 16715103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients.
    Cooney GF; Dunn SP; Kaiser B; Kulinsky AV; Mochon M; Heifets M
    Transplant Proc; 1994 Oct; 26(5):2779-80. PubMed ID: 7940876
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
    van der Pijl JW; Srivastava N; Denouël J; Burggraaf J; Schoemaker RC; van der Woude FJ; Cohen AF
    Transplantation; 1996 Aug; 62(4):456-62. PubMed ID: 8781610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile.
    Takeda A; Horike K; Onoda H; Ohtsuka Y; Yoshida A; Uchida K; Morozumi K
    Nephrology (Carlton); 2007 Apr; 12(2):197-204. PubMed ID: 17371346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.
    Lukas JC; Suárez AM; Valverde MP; Calvo MV; Lanao JM; Calvo R; Suarez E; Gil AD
    J Clin Pharm Ther; 2005 Dec; 30(6):549-57. PubMed ID: 16336287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation.
    Ohlman S; Lindholm A; Hägglund H; Säwe J; Kahan BD
    Eur J Clin Pharmacol; 1993; 44(3):265-9. PubMed ID: 8491242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine absorption profiles in pediatric kidney and liver transplant patients.
    Kovarik JM; Hoyer PF; Ettenger R; Punch J; Soergel M
    Pediatr Nephrol; 2003 Dec; 18(12):1275-9. PubMed ID: 14577021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.
    Schwinghammer TL; Przepiorka D; Venkataramanan R; Wang CP; Burckart GJ; Rosenfeld CS; Shadduck RK
    Br J Clin Pharmacol; 1991 Sep; 32(3):323-8. PubMed ID: 1777368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C1-C2 point monitoring of low-dose cyclosporin a given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome.
    Nakahata T; Tanaka H; Tsugawa K; Kudo M; Suzuki K; Ito E; Waga S
    Clin Nephrol; 2005 Oct; 64(4):258-63. PubMed ID: 16240896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant.
    Hoppu K; Jalanko H; Laine J; Holmberg C
    Transplantation; 1996 Jul; 62(1):66-71. PubMed ID: 8693548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
    Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
    Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients.
    Turgeon DK; Normolle DP; Leichtman AB; Annesley TM; Smith DE; Watkins PB
    Clin Pharmacol Ther; 1992 Nov; 52(5):471-8. PubMed ID: 1424421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
    Rostami Z; Einollahi B; Morshedi J; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.
    Abramowicz D; Manas D; Lao M; Vanrenterghem Y; Del Castillo D; Wijngaard P; Fung S;
    Transplantation; 2002 Dec; 74(12):1725-34. PubMed ID: 12499889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.